This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.
Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body. ... A proposal by Sanofi to discount the cost to the NHS of its Dupixent drug for atopic dermatitis has not been enough to sway NICE, which has said it cannot back
s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is
antibody Praluent (alirocumab) for cholesterol-lowering, IL4 inhibitor Dupixent (dupilumab) for eczema and IL-6 blocker arthritis treatment Kevzara (sarilumab) as well as a clutch of late-stage pipeline projects - before
Dupixent dulls pain of diabetes slump at Sanofi. Biosimilar competition caused steep declines in its flagship product Lantus. ... Accelerating sales of Sanofi’s new atopic dermatitis drug Dupixent helped to offset steep declines in flagship diabetes
Sanofi, Regeneron claim EU approval for eczema drug Dupixent. Analysts suggest the product could be worth 5bn at peak. ... Dupixent is also being tested for its potential in nasal polyposis, another indication where it could see competition from Nucala.
Atopic dermatitis has drawn attention in pharma of late largely due to the efforts by Sanofi and Regeneron to develop their IL-4 and IL-13-targeting drug Dupixent (dupilumab) for ... methotrexate. Dupixent seems to be making a great start in the market
More from news
Approximately 9 fully matching, plus 8 partially matching documents found.
Transforming healthcare through effective collaboration. Making work to feel proud of.
www.dovetailstrategies.com...